Background and Objectives: Coronary restenosis after drug-eluting stent (DES) implantation occurs more frequently in diabetic patients than in nondiabetic patients. We compared the parameters influencing the likelihood of restenosis after DES implantation in diabetic and nondiabetic patients. Subjects and Methods: Patients who underwent DES implantation (619 patients with 917 lesions, 211 diabetics and 408 nondiabetics), followed by 8 months coronary angiogram, were retrospectively identified using the percutaneous coronary intervention database and included in the present study [AH1]. Predictors of restenosis were identified by multivariate logistic regression analyses. Results: The baseline characteristics of the patients, such as sex, body mass index, hypertension, hyperlipidemia, and smoking status, were similar between the diabetic and nondiabetic patients. Restenosis (>50% of the diameter stenosis) occurred in 32 of 408 (7.8%) nondiabetic patients and in 32 (15.2%) of 211 diabetic patients (p<0.001). The use of a paclitaxel-eluting stent (PES), a higher level of C-reactive protein (CRP), longer stent length, smaller reference diameter (RD) before DES implantation, smaller RD and minimal lumen diameter after DES implantation were common predictors of restenosis in both the diabetic and nondiabetic patients after multivariate analyses. Current smoking status [odds ratio (OR)=3.213, 95% confidence interval (CI) 1.458 to 7.080 p=0.004] and right coronary lesions (OR=2.444, 95% CI 1.048 to 5.703, p=0.039) were predictors of restenosis in the diabetic patients, while higher body mass index (OR=1.322, 95% CI 1.054 to 1.659, p=0.016) and A-type lesions (OR=0.108, 95% CI 0.022 to 0.530, p=0.006) were predictors of restenosis in the nondiabetic patients. Conclusion: The use of PESs and higher levels of CRP were associated with restenosis regardless of the presence of diabetes. Moreover, small baseline and post-PCI reference diameter and longer stent length remained significant angiographic predictors of restenosis in both diabetic and nondiabetic patients, even in the era of DES implantation. (Korean Circ J 2007;37:530-537)
Introduction
The long-term clinical and angiographic outcomes after percutaneous coronary intervention (PCI) with baremetal stents (BMSs) have been demonstrated to be worse in diabetic patients than in nondiabetic patients. [1] [2] [3] Several studies have shown that the introduction of drugeluting stents (DESs) has significantly reduced the angiographic rates of restenosis in the later months after PCI. [4] [5] [6] [7] [8] Coronary restenosis occurs more frequently in diabetic patients than in nondiabetic patients, even after DES implantation. 9) In the era of DESs, no study has compared the clinical and angiographic predictors of coronary restenosis in diabetic and nondiabetic patients after DES implantation. 10) 11) The objective of this multicenter observational retrospective cohort study was to compare the parameters that influence coronary restenosis after DES implantation in diabetic and nondiabetic patients.
Subjects and Methods

Patient population
The patients were retrospectively identified for inclusion in the study using the Multicenter PCI Database Registry from April 2005 to August 2006. Three cardiovascular centers representing three major cities in Korea participated in the Multicenter PCI Database Registry. All clinical and angiographic data were sent to the core laboratory (Korea University, Seoul, Korea) and entered into the PCI database. From this database, DES-implanted patients (619 patients, 917 lesions)[211 diabetics, 315 lesions; 408 nondiabetics, 602 lesions] with 8 full months of clinical and angiographic followup were retrospectively included in the study. Diabetes mellitus was defined as a history of diabetes, a fasting plasma glucose concentration ≥126 mg/dL, or the use of hypoglycemic medications. Systemic hypertension was defined as a systolic blood pressure ≥140 mmHg, diastolic pressure ≥90 mmHg, or the use of antihypertensive medication. Hyperlipidemia was defined as a total cholesterol level ≥200 mg/dL, a low-density lipoprotein cholesterol level ≥130 mg/dL, or treatment with a lipid-lowering agent. A smoker was defined as someone with a current or recent history of smoking within the past year. Family history of premature coronary artery disease was defined as coronary artery disease in a male first-degree relative <55 years and female first-degree relative <65 years. Body mass index was calculated by dividing the square of the patient's height in meters from their weight in kilograms. We excluded patients with a prior history of interventional or surgical treatment for coronary artery disease, coronary artery total occlusion, or a contraindication for antiplatelet or anticoagulation therapy. Written informed consent was obtained from each patient in accordance with the Declaration of Helsinki, and the study was approved by the Korea University Hospital institutional review committees.
Drug-eluting stent implantation
Balloon angioplasty and stent implantation were performed according to standard clinical practice. The femoral or radial approach was used, and all patients were given 100 mg of aspirin combined with either 300 mg of clopidogrel or 500 mg of ticlopidine on the day before the procedure. Aspirin was given indefinitely, and 75 mg of clopidogrel or 250 mg of ticlopidine was administered once daily for 8 months. At the beginning of the intervention, a heparin bolus of 100 units/kg was administered after sheath insertion, and supplemental doses were then given to maintain an activated clotting time of >300 seconds. All patients in the study underwent balloon predilatation before stenting, and the size of the balloon was determined by the target vessel size. Either sirolimus-eluting stents (SESs) (Cypher ® , Cordis, Johnson & Johnson Corp., Miami, Florida) or paclitaxel-eluting stents (PESs) (Taxus ® , Boston Scientific Corp., Natick, Massachusetts) were selected. Highpressure balloon inflation was used in selected cases in an attempt to avoid stent underexpansion. Intravascular ultrasound (IVUS) was used in some cases if necessary. Procedural myocardial infarction was defined as the presence of new Q waves that were 0.03 seconds in width and/or one-third of the QRS complex in ≥2 contiguous leads and/or ≥3-fold increase in creatine kinase-MB concentration from the upper limit of the normal range.
Angiographic analysis
Coronary angiograms were performed at baseline, immediately after stenting, and after 8 months of followup. Two identical orthogonal views were obtained after the intracoronary administration of nitrates, and the images were stored on digital CD-ROM. End-diastolic frames were chosen for quantitative analysis using the computer-based Theoretical Computer Science system, Version 2.02 (Medcon Inc., Tel-Aviv, Israel) by an operator who was unaware of the patients' information. The average diameter of the normal segments distal and proximal to the treated lesion was used as the reference diameter. Minimal lumen diameter (MLD), percentage of stenosis, and lesion length were calculated as the average value of the two orthogonal views. The same views and calibration were used at follow-up angiography. Restenosis was defined as stenosis of >50% of the luminal diameter.
Follow-up
A complete clinical work-up was scheduled at 1 month, 4 months, and 8 months after the procedure, and angiographic follow-up was scheduled at 8 months postprocedure. All major adverse cardiovascular events (MACEs) were determined in-hospital, out-of hospital, and for 240 cumulative days after stent implantation. MACEs, which included all-cause death, myocardial infarction, and the need for repeated target lesion revascularization during the 8-month follow-up period were noted. 12-lead electrocardiography was performed immediately after the procedure and 6, 12, 24 hours following the procedure. Creatine kinase-MB activity was measured at the same time intervals. The end points were defined as cardiac death, myocardial infarction, and the need for repeated revascularization of the target vessel.
Statistical analysis
Data for the continuous variables are expressed as the mean±SD and compared with an unpaired Student's t-test. Data for the categorical variables are expressed as the number and percentage of patients, and Fisher's exact test or a chi-square test was used as needed. Multivariate logistic models were used to identify the predic-tors of coronary restenosis in the diabetic and nondiabetic patients. Quantitative coronary angiographic parameters were entered as continuous variables into the univariate logistic regression. Univariate variables with p<0.20 were entered into the multivariate logistic models. A p of <0.05 was considered significant. Statistical analysis was performed using commercially available software (SPSS 10.0 for Windows, SPSS Inc., Chicago, Illinois).
Results
Patient population
The baseline characteristics of the patients, such as sex, body mass index, hypertension, hyperlipidemia, and smoking status, were similar between the diabetic and nondiabetic patients. Restenosis (>50% of the luminal diameter stenosis during the 8 months of followup) occurred in 32 (7.8%) of 408 nondiabetic and 32 (15.2%) of 211 diabetic patients (p<0.001). The age and sex of the patients in the Restenosis Group (RG) and the No Restenosis Group (NRG) were similar in both the diabetic and nondiabetic patients ( Table 1) . The baseline C-reactive protein (CRP) levels were significantly higher in the RG than in the NRG for both the diabetic and nondiabetic patients (Table 2) .
Angiographic characteristics
The results of quantitative coronary angiography are listed in Table 3 . Lesions were characterized according to the modified American College of Cardiology/American Heart Association classification. Postprocedure reference diameter and MLD were significantly larger in the NRG than in the RG for both diabetic and nondiabetic patients (Table 3 ). In the NRG, 191 (72.3%) SESs were used compared with 23 (45.1%) SESs in the RG for diabetic patients (p<0.001)[AH2]. Similar patterns were found for nondiabetic patients; 395 (73.3%) SESs were used in the NRG while 21 (33.3%) SESs were used in the RG (p<0.001). Focal type of coronary restenosis was observed in 22 lesions (43.1%) in the diabetic 
Eight-month clinical outcomes
The rates of death (p=1.000) and myocardial infarction (p=0.180) were similar between the two groups of diabetic patients during 8 months of follow-up (Table 4) . However, the rate of myocardial infarction was higher for the nondiabetic patients in the RG (25.0% vs 9.3%, p=0.006) than in the NRG. Late stent thrombosis was observed in one diabetic patient (0.6%) in the NRG 
Multivariate analysis for predicting restenosis
The multivariate parameters for predicting restenosis in the diabetic group were current smoker, higher CRP, right coronary lesion, the use of PES, longer stent length, smaller RD before DES implantation, smaller RD after DES implantation and smaller MLD after DES implantation (Table 5 ). As shown in Table 6 , the multivariate parameters for predicting restenosis in the 
Discussion
In the present study, coronary restenosis after DES implantation remained significantly more common in diabetic patients than in nondiabetic patients (15.2% of restenosis in diabetic patients vs 7.8% in nondiabetic patients). To the best of our knowledge, no study has ever compared the clinical and angiographic parameters of coronary restenosis in diabetic and nondiabetic patients after DES implantation. Small baseline and post-PCI vessel size, longer stent length, the use of PESs, current smokers, right coronary lesions, and high levels of CRP were significant predictors of coronary restenosis in diabetic patients after DES implantation. Moreover, small baseline and post-PCI vessel size, longer stent length, the use of PESs, higher body mass index, and high level of CRP were significant predictors of restenosis in nondiabetic patients. The high level of CRP, a small baseline and post-PCI vessel size, and longer stent length remained significant predictors of restenosis in both the diabetic and nondiabetic patients, even in the era of DES implantation. In the present study, the use of PESs was associated with an increased rate of restenosis in both diabetic (OR=2.870, 95% CI 1.454 to 5.666, p=0.002) and nondiabetic patients (OR=2.657, 95% CI 1.565 to 4.512, p<0.001). Although DES implantation was found to improve the angiographic and clinical outcomes in both diabetic and nondiabetic patients when compared with BMS implantation, the angiographic predictors of restenosis after DES implantation seemed to be similar to the predictors of restenosis after BMS implantation in both diabetic and nondiabetic patients.
Coronary restenosis results from neointimal hyperplasia, which causes late luminal loss. New devices, such as DESs, can be used to reduce the rate of restenosis by decreasing the late luminal loss. The introduction of DES implantation has significantly overcome the major limitation of BMS implantation by reducing the rates of coronary restenosis. Many studies have shown that the blockage of smooth muscle cell proliferation with DESs results in the preservation of the normal vessel phenotype and function, thereby decreasing the rate of neointimal hyperplasia and coronary restenosis. [12] [13] [14] [15] Many now regard paclitaxel and sirolimuseluting stents to be the standard mode of treatment for patients undergoing PCI. The identification of the parameters of coronary restenosis after DES implantation is important since angiographic outcomes can be predicted from the baseline clinical and angiographic parameters. Moreover, modifiable risk factors, such as smoking status, in the present study could be adjusted to reduce the rate of restenosis, and patients with multiple predictors of coronary restenosis could be considered for other treatment options, such as coronary bypass surgery. Even though DES implantation lowers the rates of restenosis by preventing smoothmuscle cell proliferation at the stented site, atherosclerosis could progress at other coronary sites. Therefore, combined approaches using systemic therapies, such as HMG (3-hydroxy-3-methylglutaryl)-CoA reductase inhibitors and peroxisome proliferator-activated receptor (PPAR)-γ activators, are required to prevent neointimal proliferation and to prevent the progression of atherosclerosis at other coronary sites.
Although the total percentage of patients with restenosis after DES implantation has decreased compared with that after BMS implantation, various predictors of restenosis with DESs overlap with those associated with BMSs. [16] [17] [18] [19] [20] Notably, the angiographic parameters of restenosis in the diabetic and nondiabetic patients were similar, even after DES implantation. Since coronary restenosis was mainly the result of neointimal hyperplasia, binary restenosis was more likely to occur in patients with small baseline and post-PCI vessel diameters. Pre-and post-PCI small vessel size and longer stent length were the major angiographic predictors of restenosis, regardless of the presence of diabetes, even in the era of DES implantation. In the present study, a high level of CRP and the use of PESs were found to be associated with coronary restenosis in both diabetic and nondiabetic patients. Patients with unfavorable baseline angiographic parameters should be treated with aggressive adjunctive systemic pharmacotherapy to modify the underlying pathophysiological mechanisms responsible for neointimal formation and the progression of atherosclerosis, even in the era of DESs.
This study has the inherent limitations of every observational, nonrandomized study. It is pertinent to note that the findings of this study are based on a relatively short-term retrospective study. Moreover, the number of study participants was relatively small, and therefore we may not be able to generalize our results to all patients with DESs. The present study demonstrated the associations between various clinical and angiographic parameters and coronary restenosis; however, the causes and effects of these associations were not completely verified. IVUS studies were performed only on selected patients; therefore, it is possible that stent underexpansion and short lesion coverage may have occurred. Unexpectedly, A-type lesions were a predictor of restenosis in nondiabetic patients, and this finding might be due to the short lesion coverage and stent underexpansion by inexperienced operators. A larger prospective randomized clinical trial is warranted to confirm the various predictors of coronary restenosis after DES implantation.
In conclusion, although DES implantation was found to improve the angiographic and clinical out-comes in both diabetic and nondiabetic patients when compared with BMS implantation, coronary restenosis after DES implantation remained significantly more common in diabetic patients than in nondiabetic patients. The use of PESs, a high level of CRP, small base-line and post-PCI reference diameter, and longer stent leng-th remained significant predictors of restenosis in both the diabetic and nondiabetic patients, even in the era of DES implantation. The identification of patients with the predictors of coronary restenosis after DES implantation may aid in the alteration of the modifiable predictors of restenosis, the application of more aggressive risk factor management, and in helping interventionists to know when to consider other treatment modalities, such as coronary artery bypass graft surgery.
